Serial optical coherence tomography assessment of malapposed struts after everolimus-eluting stent implantation. A subanalysis from the HEAL-EES study.

Cardiovasc Revasc Med

Cardiology Department, Cardiovascular Institute, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain. Electronic address:

Published: February 2017

Background: Incomplete stent apposition (ISA) is related to stent thrombosis, which is a serious adverse event. We aim to assess the time-course of ISA after 2nd generation everolimus-eluting stent (EES) implantation.

Methods: In HEAL-EES study, we enrolled 36 patients who underwent percutaneous coronary intervention (PCI) with EES. OCT imaging was performed at baseline and follow-up. Patients were randomized 1:1:1 into 3 groups according to the time in which follow-up was performed: group A (6-month), group B (9-month), and group C (12-month). In this subanalysis, patients who had ISA segments at baseline and/or follow-up OCT were analyzed.

Result: At baseline, among 41 lesions in 36 patients, 20 lesions in 18 patients had ISA segments and were analyzed. At baseline, there were 3.0% ISA struts in group A (n=8), 2.8% in group B (n=4), and 4.5% in group C (n=8). At follow-up, ISA struts were present in 0.09%, 0.16% and 0.64%; respectively in groups A, B, and C. At follow-up, there was a significant decrease in the frequency of ISA: group A 3.0% vs. 0.09% (p<0.001), group B 2.8% vs. 0.16% (p<0.001), and group C 4.5% vs. 0.64% (p<0.001). In group A, there was one late acquired ISA at follow-up.

Conclusions: In patients undergoing 2nd generation EES implantation, area of acute ISA assessed by OCT, was almost resolved at 6-month follow-up.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.carrev.2016.08.010DOI Listing

Publication Analysis

Top Keywords

everolimus-eluting stent
8
heal-ees study
8
patients isa
8
isa segments
8
lesions patients
8
isa struts
8
group n=8
8
isa
7
group
7
patients
5

Similar Publications

Article Synopsis
  • This study investigates the effectiveness of bioresorbable scaffolds (IBS) versus everolimus-eluting stents (EES) for treating below-the-knee arterial disease in dogs, focusing on their support performance and effects on tissue.
  • Both types of implants were successfully used, showing similar levels of arterial narrowing within the first six months, but the IBS scaffold exhibited gradual corrosion over time.
  • Overall, the findings indicate that the IBS is comparable to EES in terms of support and tissue response within 6 months, while demonstrating a manageable corrosion profile over a year.
View Article and Find Full Text PDF

Background: Long-term clinical data on biodegradable-polymer (BP) drug-eluting stents (DES) are limited. The objective of this study was to assess the long-term safety and efficacy of the BP-DES SYNERGY compared to XIENCE V, a durable-polymer (DP)-DES.

Methods: We compared patients treated with BP-DES or DP-DES at our center from 2008 to 2020.

View Article and Find Full Text PDF

Background: Adult Kawasaki patients may require intervention for occlusive coronary artery disease. Some adverse effects of first-generation drug-eluting stent implantation with sirolimus have been reported in this population.

Methods: A total of nine lesions in eight (seven males, one female) patients who underwent stent implantations in this population between 2000 and 2021 were reviewed.

View Article and Find Full Text PDF
Article Synopsis
  • A multicenter study is assessing the safety and effectiveness of a cutting balloon angioplasty combined with a bioabsorbable polymer-coated everolimus-eluting stent for treating calcified coronary artery lesions in patients.
  • The trial involves comparing the cutting balloon (Wolverine™) to a non-compliant balloon in a group of 250 patients who have received the Synergy™ stent, focusing on outcomes like stent area, major cardiac events, and operational metrics.
  • The research aims to validate the use of cutting balloons for a range of calcified lesions, potentially influencing insurance coverage for these procedures.
View Article and Find Full Text PDF

Cost-Effectiveness of Three Different New-Generation Drug-Eluting Stents in the Randomised BIO-RESORT Trial at 3 Years.

Pharmacoecon Open

October 2024

Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ, Enschede, The Netherlands.

Background And Objective: Evidence on health economic outcomes for percutaneous coronary intervention (PCI) comparing different contemporary drug-eluting stents (DES) with each other is scarce, as most previous randomised DES trials did not assess such aspects. This prespecified health economic evaluation of the Comparison of Biodegradable Polymer and Durable Polymer Drug-Eluting Stents in an All Comers Population (BIO-RESORT) trial aimed to compare at 3-year follow-up both health effects and costs of PCI with one of three new-generation drug-eluting stents (DES) in patients with obstructive coronary artery disease.

Methods: The randomised BIO-RESORT trial assessed in 3514 patients the ultrathin-strut biodegradable polymer Orsiro sirolimus-eluting stent (SES) and very-thin-strut Synergy everolimus-eluting (EES) stent versus the thin-strut durable polymer Resolute Integrity zotarolimus-eluting stent (ZES).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!